Effect of Socio-Economic Status on Perioperative Outcomes After Robotic-Assisted Pulmonary Lobectomy

Anastasia Jermihov 1, Liwei Chen 1, Maria F. Echavarria 1, Emily P. Ng 1, Frank O. Velez 2, Carla C. Moodie 3, Joseph R. Garrett 3, Jacques P. Fontaine 5, 4, Eric M. Toloza 3, 4

1. School of Medicine, University of South Florida Health Morsani College of Medicine, Tampa, USA  2. Surgery, University of South Florida Health Morsani College of Medicine, Tampa, USA  3. Thoracic Oncology, Moffitt Cancer Center, Tampa, USA  4. Surgery and Oncologic Sciences, University of South Florida Health Morsani College of Medicine, Tampa, USA

Abstract

Background: Lower socioeconomic status (SES) has been correlated with poor survival rates and surgical outcomes following lung cancer resection. This study sought to determine whether this disparity exists perioperatively in lung cancer patients following robotic-assisted video-thoracoscopic pulmonary lobectomy.

Methods: We retrospectively reviewed 447 consecutive patients who underwent robotic-assisted pulmonary lobectomy by one surgeon for known or suspected lung cancer. Ten patients were excluded due to incomplete data. We used median income by residential ZIP code as a surrogate for SES status and grouped patients based on whether ZIP-based median income was less than (Group 1) or greater than (Group 2) 300% of the federal poverty income level. The effects of SES status groups on incidence of postoperative complications, chest tube duration, hospital length of stay (LOS), and in-hospital mortality were evaluated by the logistic regression model and Inverse Gaussian regression model, respectively.

Results: Without adjustment, Group 1 tended to have a higher rate of postoperative complications, with 54% of patients experiencing complications compared to 34% of patients in Group 2 (p=0.007). Median chest tube duration and hospital LOS were also significantly longer in Group 1 than in Group 2 (p=0.034). In multivariable logistical regression analysis, while controlling for covariates and considering effect modifications, lower SES was significantly and positively associated with postoperative complications (odds ratio (OR)=1.98, p=0.039). Preoperative chronic obstructive pulmonary disease (COPD) was also a positive and significant predictor of postoperative complications (OR=1.89, p=0.017), chest tube duration (p=0.020), and LOS (p=0.010).

Conclusions: Lower median income is associated with a greater number of postoperative complications following pulmonary resection for lung cancer when controlling for covariates.

Introduction

Lung cancer is the most common cause of cancer death in the United States (USA/US) and worldwide, claiming the lives of an estimated 1.6 million individuals each year [1, 2]. Approximately 85% of lung cancer patients will be diagnosed with the histological subgroup of non-small cell lung cancer (NSCLC) [2], of which one-fifth will have early-stage (American Joint Committee on Cancer (AJCC) stage-I and -II) disease [1]. The recommended treatment for early-stage lung cancer is surgical resection, which means that improving perioperative outcomes is an integral part of disease management.

Lower socioeconomic status (SES) has been shown to negatively influence outcomes in lung cancer patients undergoing lobectomy and other forms of surgical resection and has been associated with shorter median survival time and increased rates of in-hospital mortality and risk-adjusted mortality [3-5]. Patients with low SES demographics, such as low income, minority ethnicity, public insurance coverage, and lower levels of education, have been demonstrated to be less likely to undergo minimally invasive surgery (MIS) [6-9]. One study investigating the influence of insurance coverage on perioperative and long-term outcomes following robotic-assisted video thoracoscopic (RAVT) surgery, a form of MIS for lung cancer, found that patients with public insurance had less favorable outcomes compared to patients with private or combination insurance [10]. Since insurance coverage represents a component of SES, further research is needed to further characterize the influence of SES on outcomes after MIS for lung cancer.
Our study aims to add to the literature on the influence of SES on surgical outcomes, specifically, on MIS outcomes. The question is whether patients, who come from low SES communities and who do undergo MIS, continue to experience the adverse surgical consequences that have been associated with low SES. Area-based indicators, such as ZIP codes, have been strongly correlated with self-reported educational attainment and found to consistently detect associations between low SES and poor clinical outcomes [11]. Median income can be estimated using ZIP-code census data, and income has been identified as a significant and independent predictor of in-hospital mortality and overall survival (OS) following lung cancer resection [4,5]. Interestingly, a study investigating the degree to which individual and neighborhood SES of Black adults affect outcomes in chronic obstructive pulmonary disease (COPD) found that neighborhood-level SES, such as median household income, explained a greater percentage of racial disparities in respiratory outcomes than individual-level SES [12].

RAVT surgery is a newer modality of minimally invasive technique for lung cancer surgery comparable to conventional video-assisted thoracoscopic (VATS) surgery and is associated with reduced intraoperative blood loss and improved surgical precision [13,14]. This study aims to investigate the influence of SES on perioperative outcomes following MIS for lung cancer in the form of RAVT pulmonary lobectomy. We present the protocol in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting checklist.

This study was presented in part at the 15th Annual Academic Surgical Congress in Orlando, Florida (FL), USA, in February 2020.

Materials And Methods

We retrospectively reviewed 447 consecutive patients who underwent RAVT pulmonary lobectomy by one surgeon from September 2010 through August 2018 at a single institution, Moffitt Cancer Center, Tampa, FL, USA. This database protocol was approved by the Scientific Review Committee of Moffitt Cancer Center, Tampa, FL, USA (MCC #16728, #18761, and #19304) and by the Institutional Review Board (IRB) of the University of South Florida, Tampa, FL, USA (USF IRB #Pro00022265) and Chesapeake IRB (now Advarra), Columbia, Maryland (MD), USA (#Pro00017745 and #00000790), which waived informed consent for this retrospective study, which is considered as a review of existing data. Additionally, the patients reviewed for this study all gave informed consent for fiberoptic bronchoscopy, RAVT wedge resection and/or RAVT (completion) lobectomy, mediastinal lymph node dissection (MLND), and possible thoracotomy, the details of which have been previously described [10]. Some patients also gave informed consent for any anticipated en bloc chest wall and/or vertebral resection, with possible chest wall and/or vertebral reconstruction. Through the institutional surgical informed consent, patients gave permission to use surgery-related and tissue-related data for education and research purposes.

We used median income by residential ZIP code as a surrogate for SES, because individual income was not available. Median income census data by ZIP code was found using the American FactFinder website powered by the US Census Bureau [15]. Of the 447 consecutive patients over the 94-month period, 10 patients were excluded due to a lack of median income census data for their residential ZIP codes. Patients were grouped based on whether ZIP-based median income was less than (Group 1) or greater than (Group 2) 300% of the federal poverty income level (i.e., "below-3x-poverty" vs. "above-3x-poverty", respectively). We used the federal poverty level (FPL) for a one-person household in the year 2018, which was $12,140 according to the US Department of Health and Human Services [16]. This value of 300% of the FPL was used because there were very few patients with ZIP-based median incomes that fell below the FPL, so the cut-off was raised in order to increase the number of patients in the low-income study group enough to allow statistical comparison to the higher-income control group. A one-person household income was used based on the assumption that most patients in our study are past retirement age and could be studied as having the income of a one-person household.

In addition to the independent variable of SES by median income, other variables were analyzed, including age, gender, body surface area (BSA), body mass index (BMI), and forced expiratory volume in one second as a percentage of predicted (FEV1%) at surgery. Diffusion capacity of the lung for carbon monoxide (DLCO) was not included in our study, because not enough patients had this value recorded in their charts. Past medical history and smoking history were also obtained from the preoperative history and physical documentation. We defined current smokers as smokers who either still smoked or quit within three months of the surgical date. Former smokers include those patients who quit smoking for at least three months prior to surgery.

Primary outcomes for the study included postoperative complications, estimated blood loss (EBL), skin-to-skin procedure duration, chest tube duration, hospital LOS, and in-hospital mortality between SES groups. Mean and standard error of the mean (SEM), or else median and interquartile range (IQR), were used to report continuous variables. Number counts and percentages were used for categorical variables. Differences in means for continuous variables were compared using Student’s t-test or Wilcoxon rank-sum test (two groups), while differences in medians were compared using the Kruskal-Wallis test. We used the chi-square test or Fisher exact test to investigate the association between postoperative complications and other categorical variables.
Variables that significantly differed in univariate analyses were included in multivariable analyses. Logistic regression analysis with a stepwise selection procedure was used for the multivariable analysis of outcomes. Inverse Gaussian (\(V(\mu) = \mu^3\)) regression model was utilized to evaluate predictive variables for chest tube duration and hospital LOS [17]. Because the inverse Gaussian model uses log-link function to transform the distribution to linear, the estimate of the parameter needs to be exponentiated for an explanation, and the value denotes the factor by which each variable increases the outcome.

Survival plots were generated using the Kaplan-Meier method, with survival between groups being compared using the log-rank statistic. Survival differences between the individual clinical and pathologic stages were determined using the Cox regression method.

Statistical analyses were performed using the SAS 9.4, 2013 (SAS Institute Inc., Cary, North Carolina (NC), USA). A p-value of ≤0.05 were considered to indicate statistical significance.

## Results

### Demographics and preoperative comorbidities

Our study population comprised 437 patients, of which there were 186 (42.6%) men and 251 (57.4%) women. The mean age at surgery was 67.5 years, ranging from 24 to 87 years. There were 50 patients (11.4%) with an SES below 3x the poverty level (Group 1) and 387 (88.5%) patients with an SES above 3x the poverty level (Group 2). Preoperative pulmonary function tests showed that patients in Group 1 tended to have a lower FEV1% than patients in Group 2, but this difference did not reach significance (\(p=0.068\)), with FEV1% averaging 82.3% and 87.7%, respectively (Table 1).

When comparing preoperative comorbidities and smoking status between the two SES groups, only preoperative coronary artery disease (CAD) or myocardial infarction (MI) (26.0% vs 15.0%, \(p=0.047\)) and preoperative COPD (32.0% vs 19.4%, \(p=0.039\)) were significantly different between patients with SES below 3x poverty and those with SES above 3x poverty (Tables 1, 2). There were no significant differences in tumor size (\(p=0.758\)), histology (\(p=0.690\)), or pathologic stage (\(p=0.802\)) between the two SES groups (Table 3).

### TABLE 1: Patient Demographics

| Patient Characteristics | Total (n = 437) | SES Below 3x Poverty (n=50) | SES Above 3x Poverty (n=387) | p-value |
|-------------------------|----------------|-----------------------------|-----------------------------|---------|
| Age, yr; mean ± SEM     | 67.5 ± 0.47    | 66.4 ± 1.4                  | 67.7 ± 0.5                  | 0.280   |
| BMI, kg/m^2; mean ± SEM | 28.0 ± 0.3     | 28.2 ± 0.7                  | 28.0 ± 0.3                  | 0.773   |
| BSA, m^2; mean ± SEM    | 1.88 ± 0.01    | 1.88 ± 0.03                 | 1.88 ± 0.01                 | 0.604   |
| FEV1%, mean ± SEM       | 87.1 ± 0.9     | 82.3 ± 2.8                  | 87.7 ± 1.0                  | 0.068   |
| Gender, n (%):          |               |                            |                            |         |
| Male                    | 186 (42.6%)    | 22 (44.0%)                  | 164 (42.4%)                 | 0.827   |
| Female                  | 251 (57.4%)    | 28 (56.0%)                  | 223 (57.6%)                 |         |
| Smoking Status:         |               |                            |                            | 0.154   |
| Current smokers         | 140 (32.0%)    | 22 (44.0%)                  | 118 (30.5%)                 |         |
| Former smokers          | 218 (49.9%)    | 21 (42.0%)                  | 197 (50.9%)                 |         |
| Never                   | 79 (18.1%)     | 7 (14.0%)                   | 72 (18.6%)                  |         |

SES: socio-economic status; 3x Poverty: three-times federal poverty level; SEM: standard error of mean; BMI: body mass index; BSA: body surface area; FEV1%: forced expiratory volume in one second as percent of predicted

2022 Jermihov et al. Cureus 14(6): e26201. DOI 10.7759/cureus.26201
| Patient Comorbidities                                      | Total (n = 437) | Below 3x Poverty (n = 50) | Above 3x Poverty (n = 387) | p-value |
|-----------------------------------------------------------|-----------------|---------------------------|-----------------------------|---------|
| COPD                                                      | 91 (20.8%)      | 16 (32.0%)                | 75 (19.4%)                  | 0.039*  |
| Asthma                                                    | 32 (7.3%)       | 1 (2.0%)                  | 31 (8.1%)                   | 0.155   |
| Heart valve disease/cardioopathy                         | 28 (6.4%)       | 5 (10.0%)                 | 23 (6.0%)                   | 0.355   |
| CAD or MI                                                 | 71 (16.2%)      | 13 (26.0%)                | 58 (15.0%)                  | 0.047*  |
| CVA                                                       | 18 (4.1%)       | 4 (8.0%)                  | 14 (3.6%)                   | 0.138   |
| Cardiac abcess                                            | 22 (5.0%)       | 3 (6.0%)                  | 19 (4.9%)                   | 0.739   |
| Congestive heart failure                                  | 8 (1.8%)        | 1 (2.0%)                  | 7 (1.8%)                    | 1.000   |
| Obstructive sleep apnea                                   | 30 (6.9%)       | 2 (4.0%)                  | 28 (7.3%)                   | 0.555   |
| Pulmonary embolism                                        | 18 (4.3%)       | 3 (6.0%)                  | 16 (4.1%)                   | 0.468   |
| Prior pneumonia                                           | 38 (8.9%)       | 4 (8.0%)                  | 34 (9.0%)                   | 1.000   |
| Pulmonary fibrosis                                        | 5 (1.1%)        | 0 (0.0%)                  | 5 (1.3%)                    | 1.000   |
| Choledocholithiasan                                       | 2 (0.4%)        | 1 (2.0%)                  | 1 (0.3%)                    | 0.216   |
| Diabetes mellitus                                         | 78 (17.4%)      | 10 (20.0%)                | 68 (17.1%)                  | 0.805   |
| GERD                                                      | 87 (19.9%)      | 9 (18.0%)                 | 78 (20.2%)                  | 0.716   |
| Kidney disease                                            | 13 (3.4%)       | 2 (4.0%)                  | 11 (2.9%)                   | 0.685   |
| Chronic anemia                                            | 11 (2.5%)       | 1 (2.0%)                  | 10 (2.6%)                   | 1.000   |
| Coagulation disorders, hemophilia, thrombocytophenia      | 6 (1.4%)        | 0 (0.0%)                  | 6 (1.6%)                    | 1.000   |
| Previous cancers                                          | 185 (42.3%)     | 21 (42.0%)                | 164 (42.4%)                 | 0.980   |
| Hypertension                                              | 248 (56.6%)     | 33 (66.0%)                | 215 (55.6%)                 | 0.161   |
| Hyperlipidemia                                            | 209 (47.8%)     | 22 (44.0%)                | 187 (48.3%)                 | 0.585   |
| Atrial fibrillation                                       | 28 (6.4%)       | 1 (2.0%)                  | 27 (7.1%)                   | 0.230   |
| Other arrhythmias                                         | 26 (4.6%)       | 3 (6.0%)                  | 17 (4.4%)                   | 0.490   |
| Peripheral vascular disease                               | 17 (3.9%)       | 4 (8.0%)                  | 13 (3.4%)                   | 0.117   |
| Pancreatitis                                              | 6 (1.4%)        | 1 (2.0%)                  | 5 (1.3%)                    | 0.530   |

**TABLE 2: Smoking Status and Comorbidities**

* statistically significant (p<0.05)

3x Poverty: three-times federal poverty level; COPD: chronic obstructive pulmonary disease; CAD: coronary artery disease; MI: myocardial infarction; CVA: cerebrovascular accident; GERD: gastroesophageal reflux disease
### Tumor Characteristics

| Tumor Characteristics          | Total (n = 437) | Below 3x Poverty (n = 50) | Above 3x Poverty (n = 387) | p-value |
|-------------------------------|-----------------|---------------------------|---------------------------|---------|
| Tumor size, cm; mean ± SEM    | 3.3 ± 0.1       | 3.2 ± 0.2                 | 3.3 ± 0.1                 | 0.758   |
| Pathology, n (%)              |                 |                           |                           |         |
| Primary lung cancer           | 405 (92.7%)     | 46 (92.0%)                | 359 (92.8%)               | 0.680   |
| Pulmonary metastasis          | 26 (6.0%)       | 4 (8.0%)                  | 22 (5.7%)                 | -       |
| Other pathology‡              | 4 (0.9%)        | 0 (0.0%)                  | 4 (1.0%)                  | -       |
| Pathologic stage for primary lung cancer, n (%) | | |
| Stage IA                      | 158 (36.4%)     | 15 (30.0%)                | 143 (36.8%)               | 0.802   |
| Stage IB                      | 53 (12.1%)      | 6 (12.0%)                 | 47 (12.1%)                | -       |
| Stage IIA                     | 50 (13.5%)      | 6 (12.0%)                 | 44 (11.4%)                | -       |
| Stage IIIB                    | 70 (16.0%)      | 13 (26.0%)                | 57 (14.6%)                | -       |
| Stage IV                      | 6 (1.4%)        | 1 (2.0%)                  | 5 (1.3%)                  | -       |

### TABLE 3: Tumor Characteristics

‡ Benign or lymphoma

3x Poverty: three-times federal poverty level; SEM: standard error of mean

The incidence of various intraoperative complications was comparable between the SES groups, with no significant differences (Table 4). The rate of overall intraoperative complications, such as bleeding, phrenic or recurrent laryngeal nerve injury, bronchial injury, or diaphragmatic injury, was 8% for Group 1 and 6% for Group 2 (p=0.573). Overall conversion rates to open lobectomy were also similar, with 4% of patients in Group 1 and 6% of patients in Group 2 requiring conversion to open lobectomy (p=0.755) (Table 4).

### TABLE 4: Intraoperative Complications

3x Poverty: three-times federal poverty level

Skin-to-skin duration in minutes and EBL did not differ significantly between the two SES groups (Table 5). Group 1 did tend to have a higher rate of postoperative complications, with 27 (54%) of the 50 patients experiencing complications compared to 133 (34%) of the 387 patients in Group 2 (p=0.007) (Table 5). Among the postoperative complications, the lower SES group had greater numbers of total postoperative...
complications and of prolonged air leaks for ≥5 days (p=0.007 and 0.044, respectively) than the higher SES group (Table 6). Median chest tube duration was significantly longer in Group 1 than in Group 2 (five days vs. four days, respectively) (p=0.032) (Table 5). The same was true for median hospital LOS, which was five days in Group 1 versus four days in Group 2 (p=0.054). In-hospital mortality for Groups 1 and 2, which were 0% (0 of 50) and 1.6% (6 of 387), respectively, did not differ significantly (p=1.00) (Table 5).

| Outcomes                  | Socio-Economic Status                      | p-value |
|---------------------------|--------------------------------------------|---------|
|                           | Below 3x Poverty                          | Above 3x Poverty |         |
| Skin-to-Skin Duration, min‡ | 177 (150-235)                             | 178 (146-236)   | 0.796   |
| Estimated Blood Loss, mL‡  | 150 (100-300)                             | 150 (100-300)   | 0.494   |
| Post-Operative Complications, n (%) | 27 (54.0%)                           | 133 (34.4%)      | 0.007*  |
| Chest tube duration, days‡ | 5 (3-8)                                   | 4 (2-6)         | 0.032*  |
| Hospital LOS, days‡       | 5 (4-9)                                   | 4 (3-7)         | 0.034*  |
| In-Hospital Mortality, n (%) | 0 (0.0%)                                 | 6 (1.6%)        | 1.000   |

TABLE 5: Primary Outcomes

‡ Median (IQR)

* statistically significant (p<0.05)

3x Poverty: three-times federal poverty level; LOS: length of stay; IQR: Interquartile range
## TABLE 6: Postoperative Complications Detailed

| Complication Variables                                               | Total (n = 437) | Below 3x Poverty (n = 50) | Above 3x Poverty (n = 387) | p-value |
|---------------------------------------------------------------------|-----------------|---------------------------|-----------------------------|---------|
| Overall post-operative complications                               | 160 (36.6%)     | 27 (54.0%)                | 133 (34.4%)                 | 0.007*  |
| Pulmonary-related complications                                     |                 |                           |                             |         |
| Prolonged air leak for >5 days                                      | 92 (21.1%)      | 16 (32.0%)                | 76 (19.6%)                  | 0.044*  |
| Prolong air leak for >7 days with subcutaneous emphysema           | 84 (19.2%)      | 15 (30.0%)                | 69 (17.8%)                  | 0.049*  |
| Pneumonia                                                           | 27 (6.2%)       | 5 (10.0%)                 | 22 (5.7%)                   | 0.233   |
| Chyle leak                                                          | 18 (4.1%)       | 3 (6.0%)                  | 15 (3.9%)                   | 0.447   |
| Pneumonia after chest tube removal requiring intervention           | 8 (1.9%)        | 0 (0.0%)                  | 8 (2.1%)                    | 0.665   |
| Respiratory failure                                                 | 6 (1.4%)        | 1 (2.0%)                  | 5 (1.3%)                    | 0.520   |
| Hypoxia                                                             | 5 (1.1%)        | 1 (2.0%)                  | 4 (1.0%)                    | 0.487   |
| Aspiration                                                          |                 |                           |                             |         |
| Pneumothorax after chest tube removal requiring intervention        | 8 (1.9%)        | 0 (0.0%)                  | 8 (2.1%)                    | 0.665   |
| Respiratory failure                                                 | 6 (1.4%)        | 1 (2.0%)                  | 5 (1.3%)                    | 0.520   |
| Mucous plug requiring intervention                                  |                 |                           |                             |         |
| Mucous plug requiring intervention                                  | 17 (3.9%)       | 1 (2.0%)                  | 16 (4.1%)                   | 0.706   |
| Cardiovascular complications                                        |                 |                           |                             |         |
| Atrial fibrillation                                                 | 47 (10.8%)      | 9 (18.0%)                 | 38 (9.8%)                   | 0.079   |
| Shock/multi-organ system failure (MOSF)                             | 5 (1.1%)        | 1 (2.0%)                  | 4 (1.0%)                    | 0.487   |
| Cardiopulmonary arrest                                              | 3 (0.7%)        | 0 (0.0%)                  | 3 (0.8%)                    | 1.000   |
| Myocardial infarction (MI)                                          | 2 (0.5%)        | 0 (0.0%)                  | 2 (0.5%)                    | 1.000   |
| Cerebrovascular accident (CVA)                                      | 1 (0.2%)        | 0 (0.0%)                  | 1 (0.2%)                    | 0.114   |

‡ any arrhythmia other than atrial fibrillation

* statistically significant (p≤0.05)

3x Poverty: three-times federal poverty level; w/wo: with or without

---

### Univariate and multivariable analysis

Among baseline characteristics of patients with postoperative complications versus patients without postoperative complications, SES, age, gender, intraoperative EBL, preoperative COPD, FEV1%, hypertension, gastroesophageal reflux disease (GERD), and other arrhythmias (arrhythmias other than atrial fibrillation) were significantly associated with postoperative complications. Preoperative chronic anemia was associated with postoperative complications at a borderline significant level (Table 7).
| FEV1%*, mean ± SEM | 82.5 ± 1.6 | 89.8 ± 1.1 | <0.001* |
|---------------------|------------|------------|---------|
| Smoking, n (%)      | -          | -          | 0.118   |
| Current             | 53 (33.1)  | 87 (31.4)  |         |
| Former              | 66 (53.8)  | 132 (47.7) |         |
| Never               | 21 (13.1)  | 56 (20.9)  |         |

**TABLE 7: Baseline Characteristics of Patients with or without Postoperative Complications**

‡ any arrhythmias other than atrial fibrillation

* statistically significant (p≤0.05)

SEM: standard error of mean; IQR: inter-quartile range; EBL: estimated blood loss; FEV1%: forced expiratory volume in one second as percent of predicted

In multivariable logistical regression analysis (Table 8), the variables found to be independently positively associated with postoperative complications included Group 1 (below-3x-poverty) (Odds Ratio (OR)=1.98 vs. above-3x-poverty, 95%CI: 1.03-3.78), male gender (OR=1.70 vs female, CI: 1.10-2.64), preoperative COPD (OR=1.89, CI: 1.12-3.20), preoperative GERD (OR=1.94, CI: 1.16-3.24), preoperative other arrhythmias
Thus, low SES (below 3x federal poverty) could increase the odds of postoperative complications independent of other covariates (Figure 1).

| Variables                        | Odds Ratio (95% CI) | p-value |
|----------------------------------|---------------------|---------|
| SES Below 3x Poverty             | 1.98 (1.03, 3.78)   | 0.039   |
| Male Gender                      | 1.70 (1.10, 2.64)   | 0.018   |
| Age                              | 1.02 (1.00, 1.05)   | 0.089   |
| Estimated Blood Loss (EBL)       | 1.00 (1.00, 1.00)   | 0.92    |
| Preoperative FEV1%               | 1.00 (0.99, 1.02)   | 0.775   |
| Preoperative COPD                | 1.69 (1.12, 3.20)   | 0.017   |
| Preoperative Hypertension        | 12.50 (1.66, 94.0)  | 0.014   |
| Preoperative Other Arrhythmia‡   | 4.28 (1.59, 11.55)  | 0.004   |
| Preoperative GERD                | 1.94 (1.16, 3.24)   | 0.011   |
| Preoperative Chronic Anemia      | 0.10 (0.01, 0.87)   | 0.037   |
| Preoperative FEV1%*Pre-Op Hypertension§ | 0.98 (0.96, 0.99) | 0.026   |

**TABLE 8: Multi-Variable Logistic Regression Analysis on Predictors of Postoperative Complications**

‡ any arrhythmia other than atrial fibrillation

§ Pre-Op FEV1%*Pre-Op Hypertension = interaction between preoperative FEV1% and preoperative hypertension

CI: confidence interval; SES: socioeconomic status; 3x Poverty: three-times federal poverty level; EBL: estimated blood loss; FEV1%: forced expiratory volume in one second as percent of predicted; COPD: chronic obstructive pulmonary disease; GERD: gastroesophageal reflux disease
Preoperative hypertension forms a negative interaction with preoperative FEV1%, suggesting that preoperative FEV1% would decrease the effect of pre-operative hypertension on the odds of postoperative complications. Preoperative chronic anemia was negatively associated with post-operative complications (OR=0.10, CI: 0.01-0.87).

Patients had significantly longer chest tube durations if they had lower SES (p=0.032), male sex (p=0.008), current and former smoking status (p=0.004), and preoperative COPD, CVA, pancreatitis, and GERD (Table 9). Chest tube duration negatively correlated with both preoperative FEV1% and BMI (r=-0.16, p=0.001; r=-0.10, p=0.045; respectively). In addition, patients with preoperative chronic anemia had significantly shorter chest tube durations (p=0.021) (Table 9).
| Variables               | Chest tube duration, days | Median (IQR) | p-value‡ | LOS, days | Median (IQR) | p-value |
|------------------------|--------------------------|--------------|----------|-----------|--------------|---------|
| SES                    |                          | -            | 0.032    | -         | 5 (4-6)      | 0.034*  |
| Below 3x Poverty       |                          | 5 (3-6)      | -        | 5 (4-6)   | -            | -       |
| Above 3x Poverty       |                          | 4 (3-6)      | -        | 4 (3-7)   | -            | -       |
| Gender                 |                          | -            | 0.008    | -         | 5 (4-6)      | 0.006*  |
| Male                   |                          | 4 (3-7)      | -        | 5 (4-6)   | -            | -       |
| Female                 |                          | 3 (2-4)      | -        | 3 (2-4)   | -            | -       |
| Smoking                |                          | -            | 0.004    | -         | 3 (2-4)      | 0.001*  |
| Current Smoker         |                          | 5 (3-6.5)    | -        | 5 (3-7.5) | -            | -       |
| Former Smoker          |                          | 4 (3-6)      | -        | 5 (3-8)   | -            | -       |
| Never                  |                          | 3 (2-5)      | -        | 4 (3-5)   | -            | -       |
| Preoperative Comorbidities |                      | -            | -        | -         | -            | -       |
| COPD                   |                          | 5 (3-11)     | <0.001   | 6 (4-10)  | <0.001*     | -       |
| Hypertension           |                          | 4 (3-7)      | 0.115    | 5 (3-8)   | 0.039*      | -       |
| Pancreatitis           |                          | 16.5 (4-19)  | 0.046    | 9.5 (4-12)| 0.046*      | -       |
| GERD                   |                          | 4 (3-6)      | 0.006    | 5 (3-8)   | 0.050       | -       |
| Chronic Anemia         |                          | 2 (2-4)      | 0.021    | 4 (2-5)   | 0.055       | -       |
| Chemotherapy           |                          | 5 (4-14)     | 0.073    | 6 (4-14)  | 0.029*      | -       |
| CVA                    |                          | 5.5 (4-9)    | 0.006    | 7 (5-9)   | 0.004*      | -       |

**TABLE 9: Differences in Chest Tube Duration and Hospital Length of Stay**

‡ p-value: non-parametric Wilcoxon test

* statistically significant (p≤0.05)

IQR: interquartile range; LOS = length of stay; SES: socioeconomic status; 3x Poverty: three-times federal poverty level; COPD: chronic obstructive pulmonary disease; GERD: gastroesophageal reflux disease; CVA: cerebrovascular accident

Significantly longer hospital LOS was observed in patients of lower SES (p=0.034), male sex (p=0.006), current and former smokers (p=0.001), and preoperative COPD, hypertension, CVA, pancreatitis, and chemotherapy (Table 10). Hospital LOS also negatively correlated with preoperative FEV1% and positively correlated with age (r=-0.17, p=0.0004 and r=0.10, p=0.035; respectively).
Multi-variable analysis revealed that male gender, preoperative COPD, and preoperative GERD were independent predictors for longer chest tube duration, while BMI and preoperative chronic anemia were independent predictors for shorter chest tube duration (Table 11). Median hospital LOS for patients with preoperative COPD was 1.26 times greater than those without preoperative COPD (p<0.01). Significant positive predictors for hospital LOS also included age, preoperative FEV1%, current smoking status, and preoperative chemotherapy (Table 11). There was no significant difference in five-year OS between patients with SES below 3x poverty level and those with SES above 3x poverty level (p=0.415) (Figure 2).
| Variables                        | Exp(b)† | 95% CI† | p-value |
|---------------------------------|---------|---------|---------|
| Intercept                       | 2.49    | 1.40-4.44 | 0.002*  |
| SES below 3x Poverty†           | 1.16    | 0.94-1.43 | 0.174   |
| Male Gender                     | 1.02    | 0.99-1.16 | 0.039   |
| Age                             | 1.01    | 1.01-1.02 | <0.001* |
| Pre-Operative FEV1%†            | 1.00    | 0.99-1.00 | 0.047*  |
| Current Smoker                  | 1.28    | 1.06-1.56 | 0.012*  |
| Former Smoker                   | 1.02    | 0.88-1.18 | 0.904   |
| Pre-Operative Hypertension      | 1.04    | 0.92-1.21 | 0.527   |
| Pre-operative Chemotherapy      | 1.71    | 1.10-2.67 | 0.017*  |
| Pre-operative COPD†             | 1.26    | 1.06-1.51 | 0.010*  |
| Pre-operative Pancreatitis      | 1.24    | 0.87-1.44 | 0.130   |
| Pre-Operative CVA†              | 1.15    | 0.80-1.63 | 0.453   |

**TABLE 11: Multi-Variable Inverse Gaussian Regression Model for Hospital Length of Stay**

* statistically significant (p≤0.05)

Exp(b): exponential function of parameter (b); CI: confidence interval; SES: socioeconomic status; 3x Poverty: three-times federal poverty level; Pre-Op: preoperative; FEV1%: forced expiratory volume in one second as percent of predicted; COPD: chronic obstructive pulmonary disease; CVA: cerebrovascular disease

**FIGURE 2: Kaplan-Meier Five-Year Overall Survival Curves Based on Socio-Economic Status**

3x Poverty: three-times federal poverty level

**Discussion**

The goal of this study was to investigate if and how SES influences outcomes for the population of patients.
undergoing MIS in the form of RAVT pulmonary lobectomy. As mentioned earlier, studies have shown that patients of lower SES are less likely to undergo MIS [6-9]. Patients of low SES have been found to be less willing to undergo minimally invasive procedures and are less likely to receive novel therapies in the setting of MI and minimally invasive revascularization procedures [18,19].

Findings from this study indicate that, when controlling for covariates, lower SES was predictive for a greater number of postoperative complications following RAVT pulmonary lobectomy. Lower SES has been found to have a significant influence on risk-adjusted mortality following pulmonary lobectomy, with the odds of death increasing with declining mean income [20]. This study highlights the importance of SES influence on outcomes following MIS for lung cancer.

Additionally, patients of low SES tend to have lower scores of self-reported health (SRH) [21]. Living in low neighborhood-level median income areas and having low educational attainment contribute to a significant risk in decline of SRH over time, even in patients who remain disease-free [21]. This implies that simply living in an impoverished area or having a low SES prompts patients to believe that they have worse health. These declines in SRH observed in patients with low SES were not nearly as prominent in patients of high SES and a greater level of educational attainment [21]. The significance of this association is that poor SRH has been identified as an independent predictor of increased LOS and mortality in patients undergoing cardiac surgery [22,23]. Thus, health perception can influence outcomes independently of other factors in a postsurgical setting and could have contributed to our findings in this study.

In a study conducted by Arpey, Gaglioti, and Rosenbaum (2017), the researchers conducted in-depth interviews with patients regarding their perception of how SES affects their healthcare. Most patients reported that their SES impacted the healthcare they receive. Some patients of low SES reported that physicians treated them differently based on their SES and that they felt ashamed and hesitant to return to care [24]. Similar to the findings associated with poor SRH, negative perceptions that patients of low SES can have about their own health, the treatment they receive, and their relationship with the provider could be contributing factors to worse outcomes even in the perioperative setting of minimally invasive procedures.

To address the outcomes found in our study, physicians performing RAVT could consider performing a SRH questionnaire for patients of low SES prior to surgery to identify those patients who might be at risk for increased perioperative complications. Considering that the population of patients of low SES who have access to and undergo MIS is small, paying special attention to this population with respect to cultivating the physician-patient relationship and gauging level of comfort and trust prior to surgery may prove beneficial with respect to outcomes.

Another potential contributing factor to the results of this study is the possibility that patients of low SES delayed their surgery further than patients of higher SES. The timeframe from diagnosis to surgery was not recorded in our study and could be a point of interest for future studies. This variable has significance, because lung cancer patients residing in ZIP codes of low median income have been shown to be more likely to delay surgical resection [25], and doing so has been associated with increased postoperative complications and increased perioperative mortality [26].

Our study also demonstrated preoperative COPD to be a positive predictive variable for postoperative complications, LOS, and chest tube duration following RAVT. Although there were no differences in smoking status between our patient groups, it is possible that the differences in preoperative COPD are explained by several factors associated with lower income. Second-hand smoke, occupational exposures (such as chemicals, fumes, vapors, and dusts), indoor air pollutants (such as biomass fuels and coal), outdoor air pollutants (prevalent in urban and high-income countries), and infections are all risk factors for developing COPD [27]. In addition to the aforementioned risk factors having an association with lower SES populations, poor populations often have a higher risk of developing COPD [28-30]. Additionally, the presence of preoperative COPD in lung cancer patients has been associated with worse outcomes following surgery, including a greater number of pulmonary complications and increased 30-day mortality [31].

An unexpected finding in our study was the significant predictive value of preoperative chronic anemia for decreased LOS and postoperative complications. Preoperative anemia has been associated with increased morbidity and mortality following major non-cardiac surgery [32] and decreased OS in NSCLC patients undergoing surgical resection [33]. It is possible that these patients received increased attention and management due to their anemia, which resulted in improved outcomes. These findings may be due to differences between those and our patient populations and warrant further study.

Limitations of this study also include the fact that it was retrospective. Our study was conducted at a specialized cancer center and, therefore, may not be generalizable to the public. The choice of using 300% of the federal poverty level for a single-family home may not have been entirely representative of the household sizes encountered in our study. Additionally, while there is evidence to support the use of ZIP code median income census data as a surrogate for SES, ZIP codes can contain SES heterogeneity within their populations [4,5,11,12].
Conclusions
Lower ZIP-based median income as a surrogate for SES is associated with a greater number of postoperative complications following pulmonary resection for lung cancer after controlling for covariates. However, lower SES was not independently associated with greater chest tube duration, hospital LOS, in-hospital mortality, or OS. Thus, our study emphasizes the importance of SES awareness in the MIS setting and demonstrates that RAVT surgery is safe and feasible in patients of varying SES. Continued attention should be given to patients of low SES who undergo MIS, as they appear to be at increased risk for perioperative complications.

Additional Information
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. University of South Florida Institutional Review Board, Tampa, Florida, United States issued approval Pro00022263. The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2015). Ethical approval to report this study was obtained from the Scientific Review Committee of Moffitt Cancer Center, Tampa, United States (MCC #16728, #18761, and #19504) and by the Institutional Review Boards of University of South Florida, Tampa, Florida, United States (USF IRB 16728, and #18761 and #19504) and by the Institutional Review Boards of University of South Florida, Tampa, Florida, United States (USF IRB #Pro00022263) and Chesapeake IRB (now Advarra), Columbia, Maryland, United States (#Pro00007290). Informed consent for patient information to be published in this article was waived by our Institutional Review Boards for this retrospective study, which is considered a review of existing data. However, through our institutional surgical informed consent, patients gave permission to use surgery-related and tissue-related data for education and research purposes. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: This study was supported in part by the Health Professions Scholarship Program awarded to AJ from the United States Air Force, in part by support to AJ from the Scholarly Excellence, Leadership Experiences, and Collaborative Training (SELECT) Program of the USF Health Morsani College of Medicine and the Lehigh Valley Health Network, and in part by 2014 Summer Scholarly Awards to MFE and to EPN from the Scholarly Concentrations Program of the University of South Florida (USF) Health Morsani College of Medicine. Financial relationships: E.M.T. and J.P.F. declare(s) personal fees from Intuitive Surgical Corp. Conflict of Interest (COI)/Disclosure: EMT and JPF have had financial relationships with Intuitive Surgical, Inc., in the form of honoraria received as robotic thoracic surgery observation sites and proctors. None of the other authors have any COI to disclose. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements
We would like to acknowledge Dr. Rahul Mhaskar, who helped to identify the statistician for this study. MFE (now an MD) is currently a Clinical Associate in the Department of Pediatrics, Duke University Medical Center, Durham, NC, USA. EPN (now an MD) is currently a Resident in the Department of Psychiatry, Harbor-UCLA Medical Center, Torrance, CA, USA. FOV is currently a General Surgeon at Mission Regional Hospital, Mission, TX, USA

References
1. Groth SS, D’Cunha J: Lung cancer outcomes: the effects of socioeconomic status and race. Semin Thorac Cardiovasc Surg. 2010, 22:116-7. 10.1055/j.semtcvs.2010.08.005
2. Herbst RS, Morgensztern D, Boshoff C: The biology and management of non-small cell lung cancer. Nature. 2018, 553:446-54. 10.1038/nature25183
3. LaPar DJ, Bhamidipati CM, Harris DA, et al.: Gender, race, and socioeconomic status affects outcomes after lung cancer resections in the United States. Ann Thorac Surg. 2011, 92:434-9. 10.1016/j.thorsur.2011.04.048
4. Greenwald HP, Polissar NL, Borgatta EF, McCorkle R, Goodman G: Social factors, treatment, and survival in early-stage non-small cell lung cancer. Am J Public Health. 1998, 88:1681-4. 10.2105/ajph.88.11.1681
5. Yang R, Cheung MC, Byrne MM, Huang Y, Nguyen D, Lally BE, Koniaris LG: Do racial or socioeconomic disparities exist in lung cancer treatment?. Cancer. 2010, 116:2437-47. 10.1002/cncr.24986
6. Moss EL, Morgan G, Martin AP, Sarhanis P, Ind T: Surgical trends, outcomes and disparities in minimal invasive surgery for patients with endometrial cancer in England: a retrospective cohort study. BMJ Open. 2020, 10:e036222. 10.1136/bmjopen-2019-036222
7. Xia L, Talwar R, Taylor BL, et al.: National trends and disparities of minimally invasive surgery for localized renal cancer, 2010 to 2015. Urol Oncol. 2019, 37:182.e17-27. 10.1016/j.suronc.2018.10.028
8. Bregar AJ, Melamed A, Diver E, et al.: Minimally invasive staging surgery in women with early-stage endometrial cancer: analysis of the national cancer data base. Ann Surg Oncol. 2017, 24:1677-87. 10.1245/s10434-016-5752-8
9. Ofshetyn A, Bingmer K, Towe CW, Steinhagen E, Stein SL: Robotic proctectomy for rectal cancer in the US: a skewed population. Surg Endosc. 2020, 34:2651-6. 10.1007/s00464-019-07041-0
10. Deol PS, Sipko J, Kumar A, et al.: Effect of insurance type on perioperative outcomes after robotic-assisted pulmonary lobectomy for lung cancer. Surgery. 2019, 166:211-7. 10.1016/j.surg.2019.04.008
11. Berkowitz SA, Traore CY, Singer DE, Atlas SJ: Evaluating area-based socioeconomic status indicators for...
